B. Riley views LifeMD weight loss offering as superior to Hims & Hers

B. Riley yesterday reiterated a Buy rating on LifeMD (LFMD) with a $12 price target after Hims & Hers (HIMS) announced it offer access to GLP-1 injections. The firm thinks this “new but largely expected entrant” into the weight loss medication telehealth space will not lead to any appreciable headwinds for LifeMD. Hims & Hers’ move highlights that access to compounded GLP-1s drugs is here to stay despite some pushback from big pharma notables, the analyst tells investors in a research note. Riley views LifeMD’s offering as superior at $129 per month compared to Hims & Hers” $199 per month. Additionally, LifeMD has first mover status in the space, having already signed multiple insurance contracts, with more continued outgrowth expected in Q2, contends Riley.